RVTY
REVVITY, INC.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$162.36
−0.69%Year over year
Reported trailing growth
- Revenue
- +4.6%
- EBITDA
- +2.3%
- EBIT
- -1.3%
- EPS
- +13.3%
- Free cash flow
- +18.9%
- Operating cash flow
- +14.2%
Forward estimates
Based on analyst estimates
- Revenue
- +0.6%
- EBITDA
- +74.4%
- EPS
- +155.7%
Three-year CAGR
- Revenue
- -4.8%
- EBITDA
- -13.5%
- EBIT
- -23.0%
- Net income
- -24.8%
- EPS
- -22.7%
- Free cash flow
- -5.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Oct 1, 2026